KALA BIO, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is CRITICAL. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
KALA · Price history
Price at last available close
$0.18
−$0.33 (-65.17%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About KALA BIO, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases.
How they make money
KALA BIO, Inc. is a biopharmaceutical company currently transitioning its business model to focus on the development of Researgency.ai, an enterprise AI tool designed for biopharmaceutical teams. The company also leverages its historical clinical data and expertise in ophthalmic diseases to provide insights and services, while exploring commercial opportunities such as the distribution of genetic testing and screening programs.
Products & services
The company's primary product under development is Researgency.ai, an enterprise AI platform for clinical research. Additionally, the company holds legacy clinical data from prior ophthalmic programs and has entered into agreements for the distribution of genetic testing and screening programs in the ophthalmology sector.
Brands & revenue mix
An enterprise AI tool for biopharmaceutical teams currently under development.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Biopharmaceutical companiesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- Virotek — A commercial collaboration where KALA acts as the exclusive distributor and reseller of a genetic testing and screening program for ophthalmology in the United States, with net profits split equally between the parties.Source
Strengths
- Proprietary legacy clinical trial dataSource
Company-specific research
Questions worth answering for KALA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can KALA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is KALA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for KALA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify KALA's current valuation?
- •What does the current share basis reconciled warning mean for the reliability or interpretation of KALA's score?
Essential Investment Snapshot
Market Cap
$3.4M
P/E Ratio
-0.0
EPS
$-81.82
52-Week High
$95.50
52-Week Low
$0.40
Beta
-2.29
Analyst Target
$18.25
Shares Outstanding
19.3M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$0.47
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for KALA
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-12.0x). Earnings may be strained to cover interest expense.
M&A headline · Sep 29, 2026
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Newsfile CorpCommunity Sentiment
0 active · 0 total callsNo personal call yet on KALA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary legacy clinical trial data.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and accumulated deficits.
- −Risks associated with the development and commercialization of new AI technology.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$0.18
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -65.4%
Revenue changed sharply from 2021 to 2022. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $0.00 | $259K | $303K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | $0.00 | -$259K | -$303K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $18.8M | $21.8M | $18.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $23.6M | $18.3M | $20.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $39.2M | $40.2M | $38.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$23.4M | -$32.5M | -$36.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$39.2M | -$40.4M | -$39.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $3.3M | $5.8M | $5.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$27.0M | -$38.5M | -$42.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$27.0M | -$38.5M | -$42.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-165.50 | $-507.50 | $-867.50 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 74.2K | 163K | 75.9K | 48.6K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 74.2K | 163K | 75.9K | 48.6K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$21.32
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
-99.3%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 75.1%. Cash declined 99.3%. Total debt declined 100.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by Brokerages
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Rumor Mill · KALA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial